Kisunla: Promising Alzheimer’s Treatment Approved by US FDA as New Hope for Patients

Lilly, a manufacturing company, has announced the approval of donanemab by the US Food and Drug Administration as a treatment for Alzheimer’s disease. The drug, now known as kisunla, contains an antibody that slows the progression of Alzheimer’s by removing amyloid protein plaque in the brain. Clinical trials have shown that patients taking donanemab had a 35% lower risk of disease progression compared to those taking a placebo.

Alzheimer’s disease is a progressive degenerative disease that affects brain cells, leading to memory loss, impaired thinking, and other cognitive issues. The approval of donanemab provides another treatment option for patients in the early stages of the disease. Prof. David Tana of Rambam Medical Center described this approval as significant for patients in Israel, offering hope for slowing disease progression and potentially stopping it altogether with the removal of pathological brain proteins.

In addition to drug treatments, early diagnosis is crucial for Alzheimer’s disease. New tests such as blood tests and spinal fluid tests can help detect the disease before symptoms appear. The recent advancements in Alzheimer’s treatment offer hope for patients and their families as researchers continue to search for a cure.